Answer to Mungmunpuntipantip et al. “SARS CoV-2 vaccine AND rituximab” Joint Bone Spine 2021;88:105281

Detalles Bibliográficos
Autores principales: Verhoeven, Frank, Lepiller, Quentin, Hecquet, Sophie, Prati, Clément, Wendling, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Société française de rhumatologie. Published by Elsevier Masson SAS. 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483993/
https://www.ncbi.nlm.nih.gov/pubmed/34601112
http://dx.doi.org/10.1016/j.jbspin.2021.105283
_version_ 1784577231537831936
author Verhoeven, Frank
Lepiller, Quentin
Hecquet, Sophie
Prati, Clément
Wendling, Daniel
author_facet Verhoeven, Frank
Lepiller, Quentin
Hecquet, Sophie
Prati, Clément
Wendling, Daniel
author_sort Verhoeven, Frank
collection PubMed
description
format Online
Article
Text
id pubmed-8483993
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Société française de rhumatologie. Published by Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-84839932021-10-01 Answer to Mungmunpuntipantip et al. “SARS CoV-2 vaccine AND rituximab” Joint Bone Spine 2021;88:105281 Verhoeven, Frank Lepiller, Quentin Hecquet, Sophie Prati, Clément Wendling, Daniel Joint Bone Spine Correspondence Société française de rhumatologie. Published by Elsevier Masson SAS. 2022-01 2021-10-01 /pmc/articles/PMC8483993/ /pubmed/34601112 http://dx.doi.org/10.1016/j.jbspin.2021.105283 Text en © 2021 Société française de rhumatologie. Published by Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
Verhoeven, Frank
Lepiller, Quentin
Hecquet, Sophie
Prati, Clément
Wendling, Daniel
Answer to Mungmunpuntipantip et al. “SARS CoV-2 vaccine AND rituximab” Joint Bone Spine 2021;88:105281
title Answer to Mungmunpuntipantip et al. “SARS CoV-2 vaccine AND rituximab” Joint Bone Spine 2021;88:105281
title_full Answer to Mungmunpuntipantip et al. “SARS CoV-2 vaccine AND rituximab” Joint Bone Spine 2021;88:105281
title_fullStr Answer to Mungmunpuntipantip et al. “SARS CoV-2 vaccine AND rituximab” Joint Bone Spine 2021;88:105281
title_full_unstemmed Answer to Mungmunpuntipantip et al. “SARS CoV-2 vaccine AND rituximab” Joint Bone Spine 2021;88:105281
title_short Answer to Mungmunpuntipantip et al. “SARS CoV-2 vaccine AND rituximab” Joint Bone Spine 2021;88:105281
title_sort answer to mungmunpuntipantip et al. “sars cov-2 vaccine and rituximab” joint bone spine 2021;88:105281
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483993/
https://www.ncbi.nlm.nih.gov/pubmed/34601112
http://dx.doi.org/10.1016/j.jbspin.2021.105283
work_keys_str_mv AT verhoevenfrank answertomungmunpuntipantipetalsarscov2vaccineandrituximabjointbonespine202188105281
AT lepillerquentin answertomungmunpuntipantipetalsarscov2vaccineandrituximabjointbonespine202188105281
AT hecquetsophie answertomungmunpuntipantipetalsarscov2vaccineandrituximabjointbonespine202188105281
AT praticlement answertomungmunpuntipantipetalsarscov2vaccineandrituximabjointbonespine202188105281
AT wendlingdaniel answertomungmunpuntipantipetalsarscov2vaccineandrituximabjointbonespine202188105281

Ejemplares similares